CMV antiviral may reduce inflammation and improve immune function in people with HIV
HIV testing requirements must be simplified for injectable PrEP to have a future
Simpler PrEP services – fewer check-ups, online care – work as well as the standard approach
Beyond cholesterol: statins may protect heart health in people with HIV through multiple mechanisms
Coronary artery disease uncommon in people with HIV in Uganda
Why aren’t more people with HIV accessing doxyPEP?
HIV acquisition in women with good adherence to TAF/FTC PrEP is rare
New long-acting HIV drugs show promising early results
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians
Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise
Positive interactions with healthcare workers improve HIV care retention in Malawi and Zambia
Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment
Large fall in severe illnesses over two decades in Spain, while co-morbidities stay stable
Event-driven PrEP for women may work, modelling study predicts
PEPFAR study shows the deadly impact of stopping children’s HIV treatment
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
